| domatinostat (4SC-202) / 4SC |
2017-001770-42: EMERGE is a trial to investigate whether combining the histone deacetylase inhibitor (HDAC inhibitor) drug 4SC-202 with the immunotherapy drug avelumab is safe and improves outcomes for patients with previously treated gastroesophageal or colorectal cancer |
|
|
| Not yet recruiting | 2 | 83 | Europe | Domatinostat, Bavencio, Domatinostat, Tablet, Concentrate for solution for infusion, Bavencio | The Royal Marsden NHS Foundation Trust | Advanced gastrooesophageal and colorectal cancer, Gastric, oesophageal and bowel cancer which cannot be cured by surgery and which has been treated before with chemotherapy, Diseases [C] - Cancer [C04] | | | | |
2018-004788-30: The purpose of the research study is to determine if domatinostat in combination with avelumab will be able to delay or prevent worsening of the disease in patients with advanced unresectable/metastatic Merkel Cell Carcinoma that is continuing to grow after previous anti-PD-(L)1 antibody therapy. Furthermore, safety of the combination during the study conduct will be assessed. |
|
|
| Not yet recruiting | 2 | 40 | Europe | Domatinostat, Formulation 01, Avelumab, Domatinostat, Formulation 02, 4SC-202, MSB0010718C, Tablet, Concentrate for solution for infusion | 4SC AG, 4SC AG, Merck KgAA, A4SC AG, 4SC AG Fraunhoferstrasse 22 82152 Planegg-Martinsried, Germany | patients with advanced unresectable/metastatic Merkel Cell Carcinoma progressing on anti-PD(L)1 antibody therapy Patienten mit fortgeschrittenem, nicht resezierbaren / metastasierten Merkelzellkarzinom, bei denen unter einer Anti-PD-(L)1-Antikörpertherapie eine Progression aufgetreten ist, Metastatic, unresectable Merkel Cell Carcinoma that continues to grow after trearment with anti-PD-(L)1 antibody therapy, Diseases [C] - Cancer [C04] | | | | |
2019-003575-19: The purpose of the research study is to determine if domatinostat in combination with avelumab will be safe and effective in the treatment of metastatic Merkel Cell Carcinoma in patients who have not received any treatment of their disease |
|
|
| Not yet recruiting | 2 | 90 | Europe | Domatinostat, Avelumab, 4SC-202, MSB0010718C, Tablet, Concentrate for solution for infusion | 4SC AG, 4SC AG, Merck KgAA | treatment-naïve metastatic Merkel Cell Carcinoma, metastatic Merkel Cell Carinoma in patients who have not received any treatment of their disease, Diseases [C] - Cancer [C04] | | | | |
| Unknown status | 2 | 75 | Europe | Domatinostat, 4SC-202, Avelumab | Royal Marsden NHS Foundation Trust, 4SC AG, Merck KGaA, Darmstadt, Germany | Cancer, GI Cancer | 11/21 | 11/21 | | |
|
|
MERKLIN 2, NCT04393753: Domatinostat in Combination With Avelumab in Patients With Advanced Merkel Cell Carcinoma Progressing on Anti-PD-(L)1 |
|
|
| Completed | 2 | 19 | Europe | domatinostat in combination with avelumab | 4SC AG | Merkel Cell Carcinoma | 02/24 | 02/24 | | |
MERKLIN 1, NCT04874831: Domatinostat in Combination With Avelumab in Patients With Treatment-naïve Metastatic Merkel Cell Carcinoma |
|
|
| Withdrawn | 2 | 0 | NA | domatinostat in combination with avelumab | 4SC AG, Merck KGaA, Darmstadt, Germany | Merkel Cell Carcinoma | 09/25 | 09/25 | | |
DONIMI, NCT04133948: Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma |
|
|
| Active, not recruiting | 1/2 | 44 | Europe | Domatinostat, Nivolumab, Ipilimumab | The Netherlands Cancer Institute, 4SC | Malignant Melanoma Stage III | 01/22 | 11/24 | | |
| Completed | 1/2 | 40 | Europe | 4SC-202 in combination with Pembrolizumab | 4SC AG | Malignant Melanoma | 02/22 | 02/22 | | |
|
|
|
|
|
|
